SAN FRANCISCO, March 25 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the promotions of Michele D. Bronson, Ph.D., to vice president, regulatory and quality, Mohammad Hirmand, M.D., to vice president, clinical development, and Joyce Mordenti, Ph.D., to vice president, translational medicine.
"As we enter Phase 3 development for our lead product candidate, we are strengthening the team to lead and advance our clinical programs," said Lynn Seely, M.D., chief medical officer of Medivation. "Drs. Bronson, Hirmand and Mordenti's knowledge of the clinical trial and regulatory process will be invaluable as we move Dimebon forward in Alzheimer's and Huntington's diseases and complete our Phase 1-2 MDV3100 clinical trial in hormone-refractory prostate cancer. We look forward to their continued productivity and leadership."
Dr. Bronson joined Medivation in September 2006 as senior director, regulatory, quality and project management. She led the Company's end-of-Phase 2 meeting with the U.S. Food and Drug Administration for Dimebon(TM). Based on those discussions, Medivation plans to begin a pivotal confirmatory Phase 3 trial of Dimebon in mild-to-moderate Alzheimer's disease in the second quarter of 2008. Prior to joining Medivation, Dr. Bronson held positions of increasing responsibility in regulatory affairs at Chiron Corporation, including director in the oncology development organization, where she was responsible for approved products and developmental therapeutics. She joined Chiron Corporation from SEQUUS Pharmaceuticals where she was responsible for the development and accelerated approval of DOXIL for the treatment of ovarian cancer. Dr. Bronson began her career in drug development at Cato Research, a contract research organization. She earned a Ph.D. in molecular immunology from the University of Texas Southwestern Medical School and completed a post-doctoral fellowship at the University of California, San Francisco.
Dr. Hirmand joined Medivation as senior director, clinical development in August 2007. He has helped advance the MDV3100 clinical development program, including initiating the ongoing Phase 1-2 clinical trial in hormone-refractory prostate cancer patients. Before joining the Company, he was a senior director of clinical development at Nuvelo, Inc., where he led the clinical development department comprised of clinical operations, clinical data management and clinical sciences/medical monitor staff. Before that, he served as director of oncology development at SuperGen, Inc. and as associate director of clinical research at Amgen, Inc. (formerly Tularik, Inc.), where he led clinical development efforts for Tularik's oncology trials. Early in his career, he was a clinical scientist and manager of market development and product evaluation at Theravance, Inc. Dr. Hirmand received his M.D. from Harvard Medical School.
Dr. Mordenti joined Medivation in July 2007 as senior director, translational medicine. She has played an instrumental role in advancing all of the Company's clinical trials for Dimebon and MDV3100. Dr. Mordenti has more than 20 years of clinical and preclinical experience at multidisciplinary drug discovery and development organizations. Prior to her position at Medivation, she was senior director of drug metabolism and pharmacokinetics for Celera Genomics (formerly Axys). Before that, she held positions of increasing seniority at Genentech, including group leader/senior scientist of experimental therapeutics in the Research Division. Earlier in her career, she served as associate director of the Clinical Drug Studies Unit at the University of California, San Francisco, School of Pharmacy. She received a Ph.D. in pharmaceutical sciences from the University of Connecticut and received training as a clinical fellow at the University of California, San Francisco School of Medicine.
Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company's strategy is to identify promising product candidates, to develop them in a rapid, cost-effective manner, and to seek development and/or commercialization partners as appropriate to complement its internal efforts. For more information, please go to http://www.medivation.com.
This press release contains forward-looking statements, including statements regarding anticipated clinical trial start dates, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2007, include information about additional factors that could affect the Company's financial and operating results.
|SOURCE Medivation, Inc.|
Copyright©2008 PR Newswire.
All rights reserved